Mounjaro vs Zepbound: Same Drug, Different Label

The tirzepatide version of the Ozempic-vs-Wegovy confusion is Mounjaro versus Zepbound. Once again, these are not two different drugs. Both are tirzepatide, both are made by Eli Lilly, and the medication in the injector is the same. The split is entirely about which condition each product is approved to treat.

Surgery, hospital, doctor — illustrating Mounjaro vs Zepbound: Same Drug, Different Label

Is Mounjaro the same as Zepbound?

Tirzepatide is a dual agonist — it activates both the GLP-1 and the GIP receptor, two incretin pathways. Hitting both is the leading explanation for why tirzepatide tends to produce larger weight loss than GLP-1-only drugs. That mechanism is identical in both products.

Mounjaro was approved in 2022 for type 2 diabetes, dosed weekly and titrated across a ladder from 2.5 mg up to 15 mg. Its diabetes evidence comes from the SURPASS trial program.
Zepbound was approved in 2023 for chronic weight management in adults with obesity or overweight with a related condition, using the same 2.5-to-15 mg ladder. Its weight-loss evidence comes from the SURMOUNT program — SURMOUNT-1 reported roughly 21% average weight loss at the 15 mg dose. In 2024, Zepbound also gained an indication for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial.

Side by side

	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Manufacturer	Eli Lilly	Eli Lilly
FDA approval	2022	2023
Primary indication	Type 2 diabetes	Chronic weight management
Additional indication	—	Obstructive sleep apnea (with obesity)
Dose range	2.5–15 mg / week	2.5–15 mg / week
Route	Weekly subcutaneous injection	Weekly subcutaneous injection

Notice that, unlike Ozempic and Wegovy, the dose ladders here are the same. There’s no higher-dose obesity version — the difference is purely which label the prescription is written under.

Because Mounjaro and Zepbound share the identical molecule and dose range, the weight-loss potential is the same. What changes is the approved indication, which drives coverage and eligibility.

Mistletoe, parasitic, medicinal plant — illustrating Mounjaro vs Zepbound: Same Drug, Different Label

Why do two labels exist at all?

If the drug and the doses are identical, the natural question is why bother with two products. The answer is regulatory and commercial. FDA approvals are indication-specific, so a drug studied and cleared for diabetes needs a separate approval — and separate labeling, trials, and often separate pricing and coverage — to be marketed for obesity. Keeping the brands distinct lets the manufacturer, insurers, and pharmacies track which use a given prescription is for. It also means your insurance may cover one and not the other depending on your diagnosis, even though the vial contents don’t change.

Medical emergency, first aid, fire drill — illustrating Mounjaro vs Zepbound: Same Drug, Different Label

How do they compare to Ozempic and Wegovy?

Since people usually arrive at this comparison while also weighing the semaglutide products, the one durable point is this: tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist and, in the head-to-head SURMOUNT-5 trial, produced more weight loss than semaglutide (Wegovy). Semaglutide, in turn, carries a longer cardiovascular-outcomes record. “More weight loss on average” and “best for a specific person” are not the same claim — tolerability, cost, access, and clinical history all matter.

Frequently asked questions

Is Zepbound better than Mounjaro for weight loss?

No. They contain the same molecule at the same doses, so there is no pharmacological reason one would produce more weight loss than the other. The difference is which condition the product is approved to treat, which is what determines who can be prescribed it and whether a plan covers it.

Can you switch from Mounjaro to Zepbound?

That is a prescriber decision, and in practice it is usually a paperwork change rather than a pharmacological one — the same tirzepatide at the same dose, written under a different indication. Whether it makes sense depends on the diagnosis being treated and what the insurance plan covers.

Why does insurance cover one and not the other?

Because FDA approvals are indication-specific, and coverage follows the indication rather than the ingredient. A plan that covers diabetes medication may pay for Mounjaro and decline Zepbound for the same person, even though the vial contents are identical. This is the single most practical consequence of the two-label arrangement.

Do Mounjaro and Zepbound have the same side effects?

Yes. Identical molecule, identical dose range, so the side-effect profile is the same — the class’s gastrointestinal effects, concentrated during dose escalation. See what to do about a dose increase.

Is tirzepatide stronger than semaglutide?

For weight loss on average, yes. In SURMOUNT-5, the head-to-head trial, tirzepatide produced more weight loss than semaglutide. Semaglutide carries the deeper cardiovascular outcomes record. The full comparison covers where each has the advantage.

Which one is approved for sleep apnea?

Zepbound. It gained an indication for moderate-to-severe obstructive sleep apnea in adults with obesity in 2024, on the strength of SURMOUNT-OSA. Mounjaro does not carry that indication, even though it is the same drug.

The takeaway

Mounjaro and Zepbound are the same tirzepatide, at the same doses, cleared for different conditions — diabetes versus weight management and sleep apnea. There is no pharmacological reason to prefer one for weight loss over the other; the deciding factors are your diagnosis, what your prescriber is treating, and what your plan will cover. That’s a decision for a clinician, not a brand preference.